Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody
Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody作者机构：Department of Clinical Oncology Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong China.
出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)
年 卷 期：2012年第3卷第6期
页 面：902-911页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Colorectal Cancer Epidermal Growth Factor Receptor Cetuximab Panitumumab Strategy
摘 要：Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal strategy for their uses.
维普期刊数据库